The event is over. A replay and transcript will be available shortly.
Join us for this exciting webinar with Prothink's Analysts
Monday, November 29, 2017 from 2:00-3:00 (EST)
Successfully trading and investing in development-stage healthcare companies is a difficult task. Over 90% of drugs that are tested in the laboratory never make it to market, and only a small portion of drug candidates that move into human testing will make it across the finish line – an approved and marketed product. Most of these small companies won’t have revenues for many years as they move through development, and will require huge capital investments along the way. This often results in repeat and highly dilutive equity financings for these companies, sometimes done on the backs of retail investors. Most biotechnology companies simply won’t succeed, and identifying the quality companies in this complicated landscape is no easy task.
Investor Questions
| User | Question |
|---|
Legal Disclaimer: PropThink Digital Conferences are organized and marketed by PropThink LLC ("PropThink" or "we") with the aim of connecting subject matter experts with investors. This Digital Conference is sponsored by Bellus Health Inc. (the "Company") who has agreed to pay fifteen thousand dollars for PropThink to organize, market and host a Digital Conference featuring the Company. PropThink is not a registered investment advisor in any jurisdiction. We do not publish investment advice and remind readers that investing involves considerable risk. PropThink urges all readers to carefully review the Company's regulatory filings and consult with an investment professional before making any investment decisions. Please read our full disclaimer at http://propthink.com/disclaimer
